Loading patent…
AssigneeExponential Biotherapies, Inc.
InventorsCarl R. Merril, Richard M. Carlton, Sankar L. Adhya
Estimating the term…
The present invention is directed to bacteriophage therapy, using methods that enable the bacteriophage to delay inactivation by any and all parts of the host defense system (HDS) against foreign objects that would tend to reduce the numbers of bacteriophage and/or the efficiency of those phage at killing the host bacteria in an infection. Disclosed is a method of producing bacteriophage modified for anti-HDS purposes, one method being selection by serial passaging, and the other method being genetic engineering of a bacteriophage, so that the modified bacteriophage will remain active in the body for longer periods of time than the wild-type phage.
A method for treating an infectious disease caused by a bacteria, in an animal, comprising:
An isolated and purified bacteriophage that has a genetically inheritable ability to delay inactivation by an animal's host defense system.
A method of obtaining a bacteriophage that is able to delay inactivation by an animal's host defense system against foreign bodies, comprising:
A method of producing a bacteriophage able to delay inactivation by an animal's host defense system, comprising genetically engineering a bacteriophage to express molecules on its surface coat that delay inactivation of the bacteriophage by an animal's host defense system.
A method for treating an infectious disease caused by a bacteria, comprising administering to an animal in need of such treatment an antibiotic and/or a chemotherapeutic agent in combination with a bacteriophage specific for said bacteria, in a dosage effective to substantially eliminate the bacteria, wherein said bacteriophage has a genetically inheritable ability to delay inactivation by the animal's host defense system.
A pharmaceutical composition comprising an isolated and purified bacteriophage which has a genetically inheritable ability to delay inactivation by an animal's host defense system, in combination with a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.